首页 文献索引 SCI期刊 AI助手
期刊目录筛选

期刊名:Schizophrenia research

缩写:SCHIZOPHR RES

ISSN:0920-9964

e-ISSN:1573-2509

IF/分区:3.5/Q1

文章目录 更多期刊信息

共收录本刊相关文章索引7120
Clinical Trial Case Reports Meta-Analysis RCT Review Systematic Review
Classical Article Case Reports Clinical Study Clinical Trial Clinical Trial Protocol Comment Comparative Study Editorial Guideline Letter Meta-Analysis Multicenter Study Observational Study Randomized Controlled Trial Review Systematic Review
Naja Kirstine Andersen,Birgitte Fagerlund,Jens Richardt Møllegaard Jepsen et al. Naja Kirstine Andersen et al.
Background: The prognosis of psychosis with onset in childhood and adolescence is highly variable. This study explores long-term outcomes of early-onset psychosis (EOP) compared to controls (HC) and examines predictors of...
Anle Pan,Kai Yuan,Meihong Xiu et al. Anle Pan et al.
Background: Sleep architecture is an essential lifestyle factor influencing health and well-being, and it may offer a trans-diagnostic window to understand the shared pathophysiology across schizophrenia (SCH), bipolar di...
Katerina Konstas,Tina Gupta Katerina Konstas
Blunted affect is a prominent negative symptom of schizophrenia characterized by decreased facial, gesture, and vocal expressions. Blunted affect is prevalent in one-third of people with schizophrenia and is associated with clinical and fun...
Paul Crowley,Fiona Boland,Andrew Thompson et al. Paul Crowley et al.
Background: Reducing the duration of untreated psychosis (DUP) is a key aim of early intervention in psychosis (EIP) services. While DUP accounts for a proportion of the time individuals experience psychotic symptoms, the...
Valerio Ricci,Stefania Chiappini,Giovanni Martinotti et al. Valerio Ricci et al.
Background: Substance-induced psychotic disorders (SIPDs) present significant clinical challenges with variable outcomes. While some patients achieve complete remission following substance cessation, others develop persis...
Mehmet Murat Kırpınar,Cana Aksoy Poyraz,İrem Yıldırım et al. Mehmet Murat Kırpınar et al.
Background: Clozapine is the most effective treatment for treatment-resistant schizophrenia, however early discontinuation remains common, preventing a substantial proportion of patients from achieving its full therapeuti...